By Ana Espino | Published on February 6, 2026 | 3 min read
Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by persistent joint inflammation, which can lead to irreversible
joint damage, deformities, and significant functional impairment.
Beyond the joints, RA is associated with a systemic inflammatory state,
contributing to an increased cardiovascular risk, which remains the leading
cause of mortality in these patients.
Despite the growing efficacy of disease-modifying
antirheumatic drugs (DMARDs) and biologic therapies, many patients
experience low-grade residual inflammation that is difficult to control.
This limitation raises the question of complementary strategies capable
of targeting systemic inflammation without increasing adverse effects.
Among the therapies under
investigation, statins—primarily known for their cholesterol-lowering
properties—also exhibit documented anti-inflammatory effects,
particularly through NF-κB pathway modulation and CRP reduction.
The aim of this study was to test this hypothesis by
evaluating the impact of atorvastatin on biological markers of
inflammation and lipid parameters in patients with RA receiving
standard therapy.
Atorvastatin: a hidden anti-TNF agent?
Thirty-eight adult RA patients were randomly assigned to two
groups:
- Atorvastatin group: 40 mg/day
- Placebo group
These treatments were added to their usual antirheumatic regimen. The
study duration was
12 weeks.
Primary endpoints included C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR), tumor necrosis
factor-alpha (TNF-α), interleukin-6
(IL-6), and levels of total cholesterol, LDL, HDL, and triglycerides.
At week 12, the atorvastatin
group showed a significant reduction in CRP, TNF-α, and IL-6 compared to the placebo group. ESR
also decreased, although the between-group difference was not statistically
significant. In terms of lipid profile, atorvastatin significantly lowered total
cholesterol and LDL, with no notable changes in HDL or triglycerides.
No serious adverse events were reported, and treatment was well tolerated
overall.
A statin in the rheumatology arsenal?
Rheumatoid arthritis remains a chronic
systemic inflammatory disease that is often resistant to standard
therapies and associated with high cardiovascular risk. The main challenge today is the persistent
low-grade inflammation despite DMARDs and biologics, highlighting the need
for better-tolerated complementary strategies.
This study aimed to assess the
potential for therapeutic repurposing of atorvastatin, a widely
used statin for lowering LDL, whose anti-inflammatory effects remain
underexplored in rheumatology. The results suggest that adding atorvastatin
at 40 mg/day can significantly reduce CRP, IL-6, and TNF-α, while also improving lipid
profiles, making it a potentially valuable adjuvant option.
However, several limitations remain and justify further research.
Future studies should include larger randomized controlled trials, longer
follow-up durations, and clinical and functional assessments alongside
biological markers. Broader exploration of dose-dependent effects is
needed, along with comparisons between different statins, to identify
the optimal benefit–risk profile and integrate this approach into a personalized
management strategy for RA.
Read next: Diet and Rheumatoid Arthritis: a dose-response relationship to explore
About the author – Ana EspinoPhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.
